Brooks Laboratories Ltd

BROOKS

Watchlist

AI Mode

‌

Market Cap

₹ 287 Cr

P/E

20.58

‌

Investment Checklist

How to read checklist?

Performance

STEADY PERFORMER

Valuation

REASONABLE

Growth

STABLE

Profitability

MODERATE MARGIN

Technicals

Bearish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Brooks Laboratories Limited is a pharmaceutical manufacturing company specializing in the production of injectables, tablets, and dry syrups. It operates on a contract basis with major pharmaceutical clients.

The company has two cGMP compliant manufacturing plants located in Baddi, Himachal Pradesh, and Vadodara, Gujarat. The Vadodara facility is notably approved by the European Medicine Agency, underlining its international quality standards.

Due to strategic upgrades, Brooks Labs has enhanced its equipment and processes leading to substantial capacity improvements, especially the doubling of capacity for injectables at the Baddi plant.

Brooks Labs partners with major pharmaceutical companies such as Zydus Cadila and Wockhardt and supplies critically needed products in the parental care segment across India.

The company's Vadodara plant, recognized as the world's largest dedicated EU-certified facility, has enabled it to boost its presence and credentials in both domestic and international markets.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

Market Cap

287 Cr

Volatility

Moderate Risk

P/E Ratio

20.6

Industry P/E

30.8

PEG Ratio

0.3

P/B Ratio

2.5

52W High

202.80

52W Low

93.90

Sales CAGR

3.86%

2.36%

3.45%

10Y

0.35%

Profit CAGR

49.11%

66.10%

—

10Y

-12.95%

ROE

TTM

12.08%

-1.49%

-5.00%

10Y

-6.31%

ROCE

TTM

12.32%

-0.31%

-1.20%

10Y

-2.64%

Technicals

Oscillators

BearishNeutralBullish

Bullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
VALIANTLAB	66.82	360 Cr	71.32	1.14	0.00	1.60	1.50	1.19
TLL	300.00	351 Cr	19.63	4.19	0.00	22.08	17.36	7.60
ZIMLAB	70.45	346 Cr	52.62	1.38	0.00	2.62	6.18	1.41
BROOKS	100.00	287 Cr	20.58	2.48	0.00	12.08	12.32	9.98
LYKALABS	74.24	276 Cr	135.61	2.73	0.00	2.03	4.68	1.50
AMBASARABH	29.16	223 Cr	14.26	1.51	0.00	10.60	10.22	3.70
SYSCHEM	48.01	210 Cr	46.49	2.22	0.00	4.78	5.68	2.49

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	16	24	22	18	18	21	38	23	26	23
Expenses	16	23	21	17	18	19	37	22	22	21
Operating Profit	0.02	1.72	1.09	0.38	0.28	1.51	1.85	1.55	3.12	2.52
OPM %	0.13	7.07	5.01	2.14	1.56	7.26	4.81	6.65	12.23	10.75
Other Income	-3.89	-2.73	-4.30	-9.26	-2.13	-4.72	-5.17	-2.18	7.15	6.13
Interest	0.17	0.19	0.21	0.27	0.16	0.32	0.45	0.26	0.30	0.28
Depreciation	0.44	0.44	0.43	0.46	0.40	0.43	0.78	0.39	0.39	0.39
Profit Before Tax	-4.47	-1.64	-3.85	-9.61	-2.41	-3.96	-4.55	-1.28	9.58	7.98
Tax %	0.00	0.00	-0.78	0.00	0.00	0.00	-0.66	-14.06	0.00	0.00
Net Profit	-4.47	-1.64	-3.88	-9.61	-2.41	-3.96	-4.57	-1.46	9.58	7.98
EPS in Rs	-1.52	-0.53	-1.35	-3.36	-0.84	-1.35	-1.56	-0.54	3.25	2.71

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	77	91	63	79	83	108
Expenses	77	105	90	76	78	100
Operating Profit	0.52	-14	-26	3.22	4.94	8.03
OPM %	0.67	-15.63	-41.80	4.05	5.98	7.43
Other Income	0.73	0.80	-2.74	-20	-12	-4.92
Interest	3.10	3.10	2.18	0.84	1.03	1.33
Depreciation	7.14	7.35	7.03	1.77	1.60	1.99
Profit Before Tax	-8.99	-24	-38	-20	-9.79	-0.21
Tax %	-115.44	19.19	19.09	-0.13	-1.79	-95.24
Net Profit	-19	-19	-31	-20	-9.97	-0.41
EPS in Rs	—	-5.92	-9.03	-6.76	-4.28	3.86
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	25	25	25	26	29
Reserves	54	63	49	39	69
Borrowings	31	25	6.51	5.64	7.58
Other Liabilities	52	83	29	19	18
Total Liabilities	162	196	110	90	124
Fixed Assets	108	110	15	14	14
CWIP	0.83	15	0.00	0.00	0.00
Investments	0.02	0.06	64	43	74
Other Assets	54	71	31	34	36
Total Assets	162	196	110	90	124

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	4.46	-37	-14	-9.68	2.63
Cash from Investing Activity	-5.13	-25	0.49	0.18	-45
Cash from Financing Activity	1.16	64	11	9.60	42
Net Cash Flow	0.49	1.72	-2.58	0.10	-0.08

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2023	Aug 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Jan 2025	Mar 2025	Jun 2025	Sep 2025
Promoters	66.41%	63.59%	63.59%	63.59%	63.59%	63.59%	63.59%	59.06%	52.62%	52.62%	52.62%	52.62%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.02%	0.01%	0.00%	0.05%	0.00%	0.01%
DIIs	0.00%	1.25%	2.46%	3.86%	3.86%	3.86%	3.86%	3.86%	9.90%	10.38%	10.38%	10.38%
Public	33.59%	35.16%	33.94%	32.55%	32.55%	32.55%	32.53%	37.08%	37.48%	36.95%	37.00%	37.00%
Total Shareholders	11,216	11,141	10,686	10,028	11,432	11,543	11,282	10,521	10,375	10,537	10,317	10,078

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Nov 17, 2024	Saras gupta	Insider - Promoter Group	Disposal	137.40	1.59 Cr	1,15,404	0.43
Nov 17, 2024	Aryan mahajan	Insider - Promoter Group	Disposal	137.40	6.60 Cr	4,80,000	1.83
Nov 17, 2024	Atul ranchal	Insider - Promoter	Disposal	137.40	2.75 Cr	2,00,000	0.76
Nov 17, 2024	Atul ranchal	Insider - Promoter	Disposal	136.40	5.39 Cr	3,95,011	1.50
Nov 14, 2024	Rr family trust	Bulk	Buy	137.40	3.00 Cr	2,18,300	0.74
Nov 14, 2024	Aryan mahajan	Bulk	Sell	137.40	6.60 Cr	4,80,000	1.62
Nov 14, 2024	Atul ranchal	Bulk	Sell	137.40	2.75 Cr	2,00,000	0.67
Nov 14, 2024	One up financial consultants ...	Bulk	Buy	136.40	5.46 Cr	4,00,000	1.35
Nov 14, 2024	Atul ranchal	Bulk	Sell	136.40	5.39 Cr	3,95,011	1.34
May 16, 2024	Saravana global holdings limited	Bulk	Sell	92.12	1.27 Cr	1,38,398	0.46

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Overview

Detailed Summary

Due to strategic upgrades, Brooks Labs has enhanced its equipment and processes leading to substantial capacity improvements, especially the doubling of capacity for injectables at the Baddi plant.

Brooks Labs partners with major pharmaceutical companies such as Zydus Cadila and Wockhardt and supplies critically needed products in the parental care segment across India.

The company's Vadodara plant, recognized as the world's largest dedicated EU-certified facility, has enabled it to boost its presence and credentials in both domestic and international markets.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

Market Cap

287 Cr

Volatility

Moderate Risk

P/E Ratio

20.6

Industry P/E

30.8

PEG Ratio

0.3

P/B Ratio

2.5

52W High

202.80

52W Low

93.90

Sales CAGR

3.86%

2.36%

3.45%

10Y

0.35%

Profit CAGR

49.11%

66.10%

—

10Y

-12.95%

ROE

TTM

12.08%

-1.49%

-5.00%

10Y

-6.31%

ROCE

TTM

12.32%

-0.31%

-1.20%

10Y

-2.64%